What is InteRNA Technologies?
Based in Nijmegen, Netherlands, InteRNA Technologies is dedicated to pioneering microRNA (miRNA) therapeutics. The company's core mission involves targeting key biological processes that drive the initiation and progression of human diseases, with a particular emphasis on oncology. By leveraging its expertise in miRNA biology, InteRNA aims to develop innovative treatments that offer new hope for patients facing challenging medical conditions. The company's strategic focus on a well-defined therapeutic modality positions it within a rapidly evolving segment of the biotechnology landscape.
How much funding has InteRNA Technologies raised?
InteRNA Technologies has raised a total of $32.9M across 2 funding rounds:
Series A
$10.5M
Series B
$22.4M
Series A (2015): $10.5M with participation from INKEF Capital and Aglaia Biomedical Ventures B.V.
Series B (2021): $22.4M led by waterman-ventures.com, Oost NL, AurorA Science, and Aglaia Oncology Funds
Key Investors in InteRNA Technologies
waterman-ventures.com
Waterman Ventures is an investment entity that participated in InteRNA Technologies' Series B funding round. Further details on their specific investment focus are not provided.
Oost NL
Oost NL is a regional development agency that supports innovation and economic growth in the East Netherlands. Their investment in InteRNA Technologies indicates a focus on fostering local biotech advancements.
AurorA Science
Aurora Science is a venture capital firm that invests in promising life science companies. Their participation in InteRNA's funding round suggests a strategic interest in novel therapeutic technologies.
What's next for InteRNA Technologies?
The recent major strategic investment signifies a critical juncture for InteRNA Technologies, likely indicating a transition towards scaling its operations and advancing its lead candidates through later-stage clinical trials. This capital infusion is crucial for navigating the complex and resource-intensive path of drug development, from preclinical validation to regulatory submission. The company's ability to attract substantial backing from specialized investors highlights confidence in its scientific platform and therapeutic potential, paving the way for future growth and potential market entry.
See full InteRNA Technologies company page
